A systematic review of adverse drug events associated with administration of common asthma medications in children

PLoS ONE

Volumn 12, Issue 8, 2017, Pages

  Leung, James S ^a   Johnson, David W ^b   Sperou, Arissa J ^c   Crotts, Jennifer ^c   Saude, Erik ^b   Hartling, Lisa ^d   Stang, Antonia ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ADOLESCENT; ADVERSE DRUG REACTION; ASTHMA; CHILD; HUMAN; INFANT; INHALATIONAL DRUG ADMINISTRATION; PRESCHOOL CHILD;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFANT; LEUKOTRIENE ANTAGONISTS;

EID: 85030618913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0182738     Document Type: Article

References (87)

1. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. New England Journal of Medicine. 1995; 332(3):133-8. https://doi.org/10.1056/NEJM199501193320301 PMID: 7800004
2. Bisgaard H, Szefler S. Prevalence of asthma-like symptoms in young children. Pediatric Pulmonology. 42(8755-6863 (Print)):723-8. https://doi.org/10.1002/ppul.20644 PMID: 17598172
3. Brand PL, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA, Custovic A, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. The European respiratory journal. 2008; 32(4):1096-110. https://doi.org/10.1183/09031936.00002108 PMID: 18827155
4. Nebeker JR, Barach P, Samore MH. Clarifying Adverse Drug Events: A Clinician's Guide to Terminology, Documentation, and Reporting. Annals of Internal Medicine. 2004; 140(10):795-801. doi: https://doi.org/10.7326/0003-4819-140-10-200405180-00017 PMID: 15148066
5. Safety monitoring of medical products: reporting system for the general public. Spain: World Health Organization; 2012. 36 p.
6. Pocket Guide for Asthma Management and Prevention (for Adults and Children Older than 5 Years). Global Initiative for Asthma Management and Prevention; 2016.
7. Lougheed MD, Lemière C, Dell SD, Ducharme FM, FitzGerald JM, Leigh R, et al. Canadian Thoracic Society Asthma Management Continuum- 2010 Consensus Summary for children six years of age and over, and adults. (1198-2241 (Print)).
8. Lougheed MD, Lemiere C, Ducharme FM, Licskai C, Dell SD, Rowe BH, et al. Canadian Thoracic Society 2012 guideline update: Diagnosis and management of asthma in preschoolers, children and adults. (1198-2241 (Print)).
9. Smyth RMD, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, et al. Adverse Drug Reactions in Children-A Systematic Review. PLoS ONE. 2012; 7(3):e24061. doi: https://doi.org/10.1371/journal.pone.0024061 PMID: 22403604
10. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews. 2015; 4(1):1. doi: doi: 10.1186/2046-4053-4-1. PMID: 25554246
11. Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scole (NOS) for assessing the quality of nonrandomized studies in meta-nalyses. [cited 2016 June 22]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
12. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343.
13. Behbehani AH, Owayed AF, Hijazi ZM, Eslah EA, Al-Jazzaf AM. Cataract and ocular hypertension in children on inhaled corticosteroid therapy. Journal of Pediatric Ophthalmology and Strabismus. 2005; 42:23-7. PMID: 15724895
14. Bentur L, Bibi H, Bentur Y. Inhaled corticosteroids in young asthmatic children: association with hypercalciuria. Journal of Pharmacy Technology. 2000; 16:151-4.
15. Bentur L, Taisir J, Bentur Y. The effect of inhaled corticosteroids on the urinary calcium to creatinine ratio in childhood asthma. Therapie. 2003; 58:313-6. PMID: 14679669
16. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Annals of Allergy, Asthma, & Immunology. 2003; 91:182-8.
17. Berger WE, Qaqundah PY, Blake K, Rodriguez-Santana J, Irani A-M, Xu J, et al. Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze. Journal of Pediatrics. 2005; 146:91-5. https://doi.org/10.1016/j.jpeds.2004.08.060 PMID: 15644830
18. Berger WE, Leflein JG, Geller DE, Parasuraman B, Miller CJ, O'Brien CD, et al. The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children. Allergy & Asthma Proceedings. 2010; 31:26-39.
19. Bisgaard H, Allen D, Milanowski J, Kalev I, Willits L, Davies P. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics. 2004; 113:e87-94. PMID: 14754977
20. Chiang VW, Burns JP, Rifai N, Lipshultz SE, Adams MJ, Weiner DL. Cardiac toxicity of intravenous terbutaline for the treatment of severe asthma in children: a prospective assessment. Journal of Pediatrics. 2000; 137:73-7. https://doi.org/10.1067/mpd.2000.106567 PMID: 10891825
21. de Benedictis FM, Teper A, Green RJ, Boner AL, Williams L, Medley H, et al. Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial. Archives of Pediatrics & Adolescent Medicine. 2001; 155:1248-54.
22. Dubus JC, Marguet C, Deschildre A, Mely L, Le Roux P, Brouard J, et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy. 2001; 56:944-8. PMID: 11576072
23. Ferguson AC, Spier S, Manjra A, Versteegh FG, Mark S, Zhang P. Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. Journal of Pediatrics. 1999; 134:422-7. PMID: 10190915
24. Hinkle J, Hinson J, Kerwin E, Goodwin E, Sciarappa K, Curry L, et al. A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma. Pediatric Pulmonology. 2011; 46:761-9. https://doi.org/10.1002/ppul.21446 PMID: 21584948
25. Kaashmiri M, Shepard J, Goodman B, Lincourt WR, Trivedi R, Ellsworth A, et al. Repeat dosing of albuterol via metered-dose inhaler in infants with acute obstructive airway disease: a randomized controlled safety trial. Pediatric Emergency Care. 2010; 26:197-202. https://doi.org/10.1097/PEC. 0b013e3181d1e40d PMID: 20179658
26. Kearns GL, Lu S, Maganti L, Li XS, Migoya E, Ahmed T, et al. Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis. Journal of Clinical Pharmacology. 2008; 48:502-11. https://doi.org/10.1177/0091270008314251 PMID: 18296556
27. Kelly HW, Van Natta ML, Covar RA, Tonascia J, Grp CR. Effect of long-term corticosteroid use on bone mineral density in children: A prospective longitudinal assessment in the Childhood Asthma Management Program (CAMP) study. Pediatrics. 2008; 122:E53-E61. https://doi.org/10.1542/peds.2007-3381 PMID: 18595975
28. Kerwin EM, Tarpay MM, Kim K, Noonan MJ, Davis AM. Safety and efficacy of a new albuterol hydrofluoroalkane formulation for treating asthma symptoms in children two to less than four years of age. Pediatric Asthma Allergy & Immunology. 2006; 19:81-90.
29. Kim MK, Yen K, Redman RL, Nelson TJ, Brandos J, Hennes HM. Vomiting of liquid corticosteroids in children with asthma. Pediatric Emergency Care. 2006; 22:397-401. https://doi.org/10.1097/01.pec.0000221338.44798.6a PMID: 16801838
30. Kuusela AL, Marenk M, Sandahl G, Sanderud J, Nikolajev K, Persson B. Comparative study using oral solutions of bambuterol once daily or terbutaline three times daily in 2-5-year-old children with asthma. Bambuterol Multicentre Study Group. Pediatric Pulmonology. 2000; 29:194-201. PMID: 10686040
31. Leflein JG, Gawchik SM, Galant SP, Lyzell E, Young M, Cruz-Rivera M, et al. Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma. Allergy & Asthma Proceedings. 2001; 22:359-66.
32. Leflein JG, Baker JW, Eigen H, Lyzell E, McDermott L. Safety features of budesonide inhalation suspension in the long-term treatment of asthma in young children. Advances in Therapy. 2005; 22:198-207. PMID: 16236681
33. MacKenzie CA, Tsanakas J, Tabachnik E, Radford M, Berdel D, Gotz MH, et al. An open study to assess the long-term safety of fluticasone propionate in asthmatic children. British Journal of Clinical Practice. 1994; 48:15-8. PMID: 8179974
34. Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Annals of Allergy, Asthma, & Immunology. 2005; 95:66-71.
35. Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Current Medical Research & Opinion. 2011; 27:163-9.
36. Noonan M, Karpel JP, Bensch GW, Ramsdell JW, Webb DR, Nolop KB, et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Annals of Allergy, Asthma, & Immunology. 2001; 86:36-43.
37. Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S, Lindh A, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. European Respiratory Journal. 2003; 22:787-94. PMID: 14621086
38. Roux C, Kolta S, Desfougeres JL, Minini P, Bidat E. Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthma. Pediatrics. 2003; 111:E706-E13. PMID: 12777589
39. Silverman M, Sheffer AL, Diaz PV, Lindberg B. Safety and tolerability of inhaled budesonide in children in the Steroid Treatment As Regular Therapy in early asthma (START) trial. Pediatric Allergy & Immunology. 2006; 17 Suppl 17:14-20.
40. Skoner DP, Greos LS, Kim KT, Roach JM, Parsey M, Baumgartner RA. Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma. Pediatric Pulmonology. 2005; 40:477-86. https://doi.org/10.1002/ppul.20288 PMID: 16193496
41. Skoner DP, Maspero J, Banerji D, Ciclesonide Pediatric Growth Study G. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics. 2008; 121:e1-14. https://doi.org/10.1542/peds.2006-2206 PMID: 18070931
42. Skoner DP, Gentile DA, Angelini B. Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. Allergy and Asthma Proceedings. 2010; 31:10-9. https://doi.org/10.2500/aap.2010.31.3305 PMID: 20167141
43. van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Current Medical Research & Opinion. 2005; 21:971-9.
44. Watson WT, Shuckett EP, Becker AB, Simons FE. Effect of nebulized ipratropium bromide on intraocular pressures in children. Chest. 1994; 105:1439-41. PMID: 8181333
45. Weinstein S, Chervinsky P, Pollard SJ, Bronsky EA, Nathan RA, Prenner B, et al. A one-week dose-ranging study of inhaled salmeterol in children with asthma. Journal of Asthma. 1997; 34:43-52. PMID: 9033439
46. Wolthers OD, Walters EG. Short-term lower leg growth in 5- to 11-year-old asthmatic children using beclomethasone dipropionate inhalers with chlorofluorocarbon or hydrofluoroalkane propellants: a 9-week, open-label, randomized, crossover, noninferiority study. Clinical Therapeutics. 2011; 33:1069-76. https://doi.org/10.1016/j.clinthera.2011.06.015 PMID: 21784529
47. Zarkovic JP, Marenk M, Valovirta E, Kuusela AL, Sandahl G, Persson B, et al. One-year safety study with bambuterol once daily and terbutaline three times daily in 2-12-year-old children with asthma. The Bambuterol Multicentre Study Group. Pediatric Pulmonology. 2000; 29:424-9. PMID: 10821722
48. Abusamra R, Avanis MC, Liu YM, Vaidya M. Think again: Salbutamol therapy in acute wheeze. Intensive Care Medicine. 2013; 39:S154-S5. doi: http://dx.doi.org/10.1007/s00134-013-2950-8.
49. Baumann SF, Baumann SS, Pakaski S, Deanovic M, Radic V. Body height and body mass index of male children with asthma on long-term treatment with inhaled corticosteroids in Pancevo Serbia. Pediatric Pulmonology. 2014; 49:S62. doi: http://dx.doi.org/10.1002/ppul.23068.
50. Cavkaytar O, Vuralli D, Arik Yilmaz E, Buyuktiryaki B, Soyer O, Sahiner UM, et al. Evidence of hypothalamic-pituitary-adrenal axis suppression during moderate-to-high-dose inhaled corticosteroid use. Eur J Pediatr. 2015; 174(11):1421-31. doi: http://dx.doi.org/10.1007/s00431-015-2610-9. https://doi.org/10.1007/s00431-015-2610-9 PMID: 26255048
51. Egelund TA, Wassil SK, Edwards EM, Linden S, Irazuzta JE. High-dose magnesium sulfate infusion protocol for status asthmaticus: a safety and pharmacokinetics cohort study. Intensive Care Medicine. 2013; 39(1):117-22. doi: http://dx.doi.org/10.1007/s00134-012-2734-6. https://doi.org/10.1007/ s00134-012-2734-6 PMID: 23129148
52. Erdem SB, Nacaroglu HT, Karkiner CSU, Gunay I, Can D. Side effects of leukotriene receptor antagonists in asthmatic children. Iranian Journal of Pediatrics. 2015; 25 (5) (no pagination)(e3313). doi: http://dx.doi.org/10.5812/ijp.3313.
53. Fagbuyi DB, Venkataraman S, Ralphe JC, Zuckerbraun NS, Pitetti RD, Lin Y, et al. Diastolic Hypotension, Troponin Elevation, and Electrocardiographic Changes Associated With the Management of Moderate to Severe Asthma in Children. Academic Emergency Medicine. 2016; 23(7):816-22. doi: http://dx.doi.org/10.1111/acem.12997. https://doi.org/10.1111/acem.12997 PMID: 27129445
54. Kenyon CC, Fieldston ES, Luan X, Keren R, Zorc JJ. Safety and effectiveness of continuous aerosolized albuterol in the non-intensive care setting. Pediatrics. 2014; 134(4):e976-82. doi: http://dx.doi.org/10.1542/peds.2014-0907. https://doi.org/10.1542/peds.2014-0907 PMID: 25266428
55. Perry RJ, Schwarz W, Stosky K, Dawrant J, Pacaud D, Noseworthy M, et al. Zenhale-inhaled corticosteroid therapy: Useful second-line therapy for asthma in children but be wary of adrenal suppression. Canadian Journal of Diabetes. 2014; 38:S2.
56. Sarnaik SM, Saladino RA, Manole M, Pitetti RA, Arora G, Kuch BA, et al. Diastolic hypotension is an unrecognized risk factor for beta-agonist-associated myocardial injury in children with asthma. Pediatric Critical Care Medicine. 2013; 14(6):e273-e9. doi: http://dx.doi.org/10.1097/PCC.0b013e31828a7677.https://doi.org/10.1097/PCC.0b013e31828a7677 PMID: 23823208
57. Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, et al. Safety of adding salmeterol to fluticasone propionate in children with asthma. New England Journal of Medicine. 2016; 375(9):840-9. doi: http://dx.doi.org/10.1056/NEJMoa1606356. https://doi.org/10.1056/NEJMoa1606356 PMID: 27579634
58. Wisecup S, Eades S, Hashmi SS, Samuels C, Mosquera RA. Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol. Journal of Asthma. 2015; 52(7):693-8. https://doi.org/10.3109/02770903.2014.1002566 PMID: 25738493
59. Aagaard L, Hansen E. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011. International Journal of Clinical Pharmacy. 2014; 36(6):1222-9. doi: https://doi.org/10.1007/s11096-014-0020-0 PMID: 25288145
60. The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment [cited 2016 June 24]. Available from: http://who-umc.org/Graphics/24734.pdf.
61. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics. 1981; 30(2):239-45. doi: https://doi.org/10.1038/clpt.1981.154
62. Rehan HS, Chopra D, Kakkar AK. Physician's guide to pharmacovigilance: Terminology and causality assessment. European Journal of Internal Medicine. 2009; 20(1):3-8. doi: http://dx.doi.org/10.1016/j.ejim.2008.04.019. https://doi.org/10.1016/j.ejim.2008.04.019 PMID: 19237084
63. National Coordinating Council for Medication Error Reporting and Prevention: Types of Medication Errors 1996 [updated 2001 Feb 21; cited 2016 June 24]. Available from: http://www.nccmerp.org/typesmedication-errors.
64. U.S. Food and Drug Administration: What is a Serious Adverse Event Silver Spring, MA [updated 02/ 01/2016; cited 2016 June 24]. Available from: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm.
65. Aagaard L, Hansen EH. Adverse drug reactions associated with asthma medications in children: systematic review of clinical trials. International Journal of Clinical Pharmacy. 2014; 36(2):243-52. Epub 2014 Feb 23. doi: https://doi.org/10.1007/s11096-014-9924-y PMID: 24562976
66. Allen DB. Inhaled corticosteroids and growth: still an issue after all these years. Journal of pediatrics. 2015; 166(2):463-9. Epub 2014 Nov 12. doi: https://doi.org/10.1016/j.jpeds.2014.09.055 PMID: 25631291
67. Creese KH, Doull IJ. Effects of inhaled corticosteroids on growth in asthmatic children. Current Allergy and Asthma Reports. 2001; 1(2):122-6. PMID: 11899294
68. Bartholow AK, DD M., Skoner JM, Skoner DP. A critical review of the effects of inhaled corticosteroids on growth. Allergy and Asthma Proceedings. 2013; 34(5):391-407. doi: https://doi.org/10.2500/aap.2013.34.3689 PMID: 23998236
69. Kapadia CR, Nebesio TD, Myers SE, Willi S, Miller BS, Allen DB, et al. Endocrine Effects of Inhaled Corticosteroids in Children. JAMA Pediatrics. 2016; 170(2):163-70. doi: https://doi.org/10.1001/jamapediatrics.2015.3526 PMID: 26720105
70. Fuhlbrigge AL, Kelly HW. Inhaled corticosteroids in children: effects on bone mineral density and growth. The Lancet Respiratory Medicine. 2014; 2(6):487-96. doi: https://doi.org/10.1016/S2213-2600 (14)70024-4 PMID: 24717638
71. Gupta R, Fonacier L. Adverse Effects of Nonsystemic Steroids (Inhaled, Intranasal, and Cutaneous): a Review of the Literature and Suggested Monitoring Tool. Current Allergy and Asthma Reports. 2016; 16 (6):1-11. doi: https://doi.org/10.1007/s11882-016-0620-y PMID: 27207481
72. Loke YK, Gilbert D, Thavarajah M, Blanco P, Wilson AM. Bone mineral density and fracture risk with long-term use of inhaled corticosteroids in patients with asthma: systematic review and meta-analysis. BMJ Open. 2015; 5(11):e008554. doi: https://doi.org/10.1136/bmjopen-2015-008554 PMID: 26603243
73. Loke YK, Blanco P, Thavarajah M, Wilson AM. Impact of Inhaled Corticosteroids on Growth in Children with Asthma: Systematic Review and Meta-Analysis. PLoS ONE. 2015; 10(7):e0133428. doi: https://doi.org/10.1371/journal.pone.0133428 PMID: 26191797
74. Skoner DP. Inhaled corticosteroids: Effects on growth and bone health. Annals of Allergy, Asthma & Immunology. 2016; 117(6):595-600. doi: https://doi.org/10.1016/j.anai.2016.07.043 PMID: 27979015
75. Pedersen S. Clinical Safety of Inhaled Corticosteroids for Asthma in Children. Drug Safety. 2006; 29 (7):599-612. doi: https://doi.org/10.2165/00002018-200629070-00005 PMID: 16808552
76. Loke YK, Blanco P, Thavarajah M, Wilson AM. Impact of Inhaled Corticosteroids on Growth in Children with Asthma: Systematic Review and Meta-Analysis. PLoS ONE. 2015; 10(7):e01332428.
77. Zhang L, P S., Ducharme FM. Inhaled corticosteroids in children with persistent asthma: effects on growth. Evidence-based child health: a Cochrane review journal. 2014; 9(4):829-930. doi: https://doi.org/10.1002/ebch.1988 PMID: 25504972
78. Kowalski ML, P W, Dziewonska M, Rys P. Adrenal suppression by inhaled corticosteroids in patients with asthma: A systematic review and quantitative analysis. Allergy and Asthma Proceedings. 2016; 37 (1):9-17. doi: https://doi.org/10.2500/aap.2016.37.3912 PMID: 26831841
79. Issa-El-Khoury K, Kim H, Chan ES, Vander Leek T, Noya F. CSACI position statement: systemic effect of inhaled corticosteroids on adrenal suppression in the management of pediatric asthma. Allergy, Asthma, and Clinical Immunology. 2015; 11(1):9. doi: https://doi.org/10.1186/s13223-015-0075-z PMID: 25802532
80. Wooltorton E. Salmeterol (Serevent) asthma trial halted early. CMAJ. 2003; 168(6):738. PMID: 12642431
81. Martinez FD. Safety of long-acting beta-agonists-an urgent need to clear the air. New England Journal of Medicine. 2005; 353(25):2637-9. https://doi.org/10.1056/NEJMp058299 PMID: 16371628
82. Levenson M. Long-Acting-Beta-Agonists and Adverse Asthma Events Meta-Analysis Sliver Spring, MD: Food and Drug Administration; 2008 [updated November 12, 2008; cited 2017 June 16]. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf.
83. Cates CJ, Oleszczuk M, Stovold E, Wieland LS. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews. 2012; 17 (10):10:CD010005. doi: https://doi.org/10.1002/14651858.CD010005.pub2 PMID: 23076961
84. Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, RT F., et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol. 2009; 124(4):691-6.e6. doi: https://doi.org/10.1016/j.jaci.2009.08.010 PMID: 19815114
85. Schumock GT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study. J Allergy Clin Immunol. 2012; 130(2):368-75. Epub 2012 Jun 12. doi: https://doi.org/10.1016/j.jaci.2012.04.035 PMID: 22698520
86. Calapai G, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology. 2014; 94(1-2):60-70. Epub 2014 Sep 2. doi: https://doi.org/10.1159/000366164 PMID: 25196099
87. Aldea Perona A, Garcia-Saiz M, Sanz Alvarez EA-Ohoo. Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase((R)). Drug Safety. 2016; 39(1):69-78. https://doi.org/10.1007/s40264-015-0360-2 PMID: 26620206